NewsNovo

Adial Pharmaceuticals adjourns annual meeting pending Nasdaq approval

10/17/2026

has adjourned its 2026 Annual Meeting of Stockholders for a second time regarding four specific proposals, citing the absence of a required Nasdaq conditional approval.

The company filed an 8-K with the Securities and Exchange Commission on October 15, 2026, to disclose that it reconvened the meeting that day but chose to extend the delay for Proposals 3, 4, 5, and 6.

The remaining proposals had already been voted upon at the initial convening in September. The next scheduled reconvene date for the pending items is October 26, 2026.

The initial delay stemmed from the company's need to secure Nasdaq's conditional approval of an Initial Listing Application related to the proposals presented at the annual meeting.

Keep reading

Read the full story

Open on NewsNovo